Cutting edge: FasL+ immune cells promote resolution of fibrosis

Journal of Autoimmunity

Volumn 59, Issue , 2015, Pages 67-76

  Wallach Dayan, Shulamit B ^a   Elkayam, Liron ^a   Golan Gerstl, Regina ^a   Konikov, Jenya ^a   Zisman, Philip ^a   Dayan, Mark Richter ^b   Arish, Nissim ^a   Breuer, Raphael ^a,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FasL; Immune cells; Lung fibrosis resolution; Myofibroblast apoptosis; SFasL

Indexed keywords

CD4 ANTIGEN; FAS LIGAND; BLOCKING ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANIMAL; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; FIBROSIS; GENE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; METABOLISM; PATHOLOGY; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, BLOCKING; APOPTOSIS; CELLS, CULTURED; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; FIBROSIS; GENES, RAG-1; HUMANS; IMMUNOLOGIC SURVEILLANCE; LUNG; MICE; MICE, KNOCKOUT; MICE, SCID; MYOFIBROBLASTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84928585996     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.02.006     Document Type: Article

References (54)

1. Kuwano K., Maeyama T., Inoshima I., Ninomiya K., Hagimoto N., Yoshimi M., et al. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases. Respirology 2002, 7:15-21.
2. Kuwano K., Kawasaki M., Maeyama T., Hagimoto N., Nakamura N., Shirakawa K., et al. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 2000, 118:451-458.
3. Tanaka T., Yoshimi M., Maeyama T., Hagimoto N., Kuwano K., Hara N. Resistance to Fas-mediated apoptosis in human lung fibroblast. Eur. Respir. J. 2002, 20:359-368.
4. Buhling F., Wille A., Rocken C., Wiesner O., Baier A., Meinecke I., et al. Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir. Res. 2005, 6:37.
5. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J.Exp. Med. 1997, 186:2045-2050.
6. Hanabuchi S., Koyanagi M., Kawasaki A., Shinohara N., Matsuzawa A., Nishimura Y., et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4930-4934.
7. Stalder T., Hahn S., Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J.Immunol. 1994, 152:1127-1133.
8. Hahn S., Gehri R., Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 1995, 146:57-79.
9. Melief C.J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 1992, 58:143-175.
10. Peter M.E., Krammer P.H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 1998, 10:545-551.
11. Nagata S., Golstein P. The Fas death factor. Science 1995, 267:1449-1456.
12. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
13. Golan-Gerstl R., Wallach-Dayan S.B., Amir G., Breuer R. Epithelial cell apoptosis by fas ligand-positive myofibroblasts in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2007, 36:270-275.
14. Wallach-Dayan S.B., Golan-Gerstl R., Breuer R. Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20460-20465.
15. Golan-Gerstl R., Wallach-Dayan S.B., Zisman P., Cardoso W.V., Goldstein R.H., Breuer R. Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 47:271-279.
16. Pilewski J.M., Liu L., Henry A.C., Knauer A.V., Feghali-Bostwick C.A. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am. J. Pathol. 2005, 166:399-407.
17. Kremer S., Breuer R., Lossos I.S., Berkman N., Christensen T.G., Connor M.W., et al. Effect of immunomodulators on bleomycin-induced lung injury. Respiration 1999, 66:455-462.
18. Gokhale S., Rosen D., Sneige N., Diaz L.K., Resetkova E., Sahin A., et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 2007, 15:451-455.
19. Wallach-Dayan S.B., Izbicki G., Cohen P.Y., Gerstl-Golan R., Fine A., Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L790-L796.
20. Schulte M., Reiss K., Lettau M., Maretzky T., Ludwig A., Hartmann D., et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007, 14:1040-1049.
21. Fujioka H., Hunt P.J., Rozga J., Wu G.D., Cramer D.V., Demetriou A.A., et al. Carboxyfluorescein (CFSE) labelling of hepatocytes for short-term localization following intraportal transplantation. Cell Transplant. 1994, 3:397-408.
22. Li X., Dancausse H., Grijalva I., Oliveira M., Levi A.D. Labeling Schwann cells with CFSE - an invitro and invivo study. J.Neurosci. Methods 2003, 125:83-91.
23. Lo Re S., Lison D., Huaux F. CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions. J.Leukoc. Biol. 2013, 93:499-510.
24. Luzina I.G., Todd N.W., Iacono A.T., Atamas S.P. Roles of T lymphocytes in pulmonary fibrosis. J.Leukoc. Biol. 2008, 83:237-244.
25. Downey G.P. Resolving the scar of pulmonary fibrosis. N.Engl. J. Med. 2011, 365:1140-1141.
26. Fireman E., Vardinon N., Burke M., Spizer S., Levin S., Endler A., et al. Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis. Eur. Respir. J. 1998, 11:706-711.
27. Corsini E., Luster M.I., Mahler J., Craig W.A., Blazka M.E., Rosenthal G.J. Aprotective role for T lymphocytes in asbestos-induced pulmonary inflammation and collagen deposition. Am. J. Respir. Cell Mol. Biol. 1994, 11:531-539.
28. Helene M., Lake-Bullock V., Zhu J., Hao H., Cohen D.A., Kaplan A.M. Tcell independence of bleomycin-induced pulmonary fibrosis. J.Leukoc. Biol. 1999, 65:187-195.
29. Collins S.L., Chan-Li Y., Hallowell R.W., Powell J.D., Horton M.R. Pulmonary vaccination as a novel treatment for lung fibrosis. PLoS ONE 2012, 7:e31299.
30. Kuwano K., Miyazaki H., Hagimoto N., Kawasaki M., Fujita M., Kunitake R., et al. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am. J. Respir. Cell Mol. Biol. 1999, 20:53-60.
31. Khalil N., O'Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ 2004, 171:153-160.
32. Moodley Y.P., Caterina P., Scaffidi A.K., Misso N.L., Papadimitriou J.M., McAnulty R.J., et al. Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis. J.Pathol. 2004, 202:486-495.
33. Conceicao-Silva F., Hahne M., Schroter M., Louis J., Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur. J. Immunol. 1998, 28:237-245.
34. Cohen P.L., Eisenberg R.A. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol. Today 1992, 13:427-428.
35. Kuwano K., Hagimoto N., Kawasaki M., Yatomi T., Nakamura N., Nagata S., et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J.Clin. Invest. 1999, 104:13-19.
36. Aoshiba K., Yasui S., Tamaoki J., Nagai A. The Fas/Fas-ligand system is not required for bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 2000, 162:695-700.
37. Saunders N.A., Smith R.J., Jetten A.M. Differential responsiveness of human bronchial epithelial cells, lung carcinoma cells, and bronchial fibroblasts to interferon-gamma invitro. Am. J. Respir. Cell Mol. Biol. 1994, 11:147-152.
38. Piela T.H., Korn J.H. Lymphocyte-fibroblast adhesion induced by interferon-gamma. Cell. Immunol. 1988, 114:149-160.
39. Sempowski G.D., Chess P.R., Phipps R.P. CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. J.Immunol. 1997, 158:4670-4677.
40. Schattner E.J., Elkon K.B., Yoo D.H., Tumang J., Krammer P.H., Crow M.K., et al. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J.Exp. Med. 1995, 182:1557-1565.
41. Hohlbaum A.M., Moe S., Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J.Exp. Med. 2000, 191:1209-1220.
42. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J.Exp. Med. 1998, 187:1205-1213.
43. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 1998, 4:31-36.
44. Mogi M., Fukuo K., Yang J., Suhara T., Ogihara T. Hypoxia stimulates release of the soluble form of fas ligand that inhibits endothelial cell apoptosis. Lab. Invest. 2001, 81:177-184.
45. Elicker B.M., Golden J.A., Ordovas K.G., Leard L., Golden T.R., Hays S.R. Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis. Respir. Med. 2010, 104:426-433.
46. Crothers K., Huang L., Goulet J.L., Goetz M.B., Brown S.T., Rodriguez-Barradas M.C., et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 2011, 183:388-395.
47. Ozsahin H., Arredondo-Vega F.X., Santisteban I., Fuhrer H., Tuchschmid P., Jochum W., et al. Adenosine deaminase deficiency in adults. Blood 1997, 89:2849-2855.
48. Schroeder S.A., Swift M., Sandoval C., Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr. Pulmonol. 2005, 39:537-543.
49. Somech R., Somers G.R., Chitayat D., Grunebaum E., Atkinson A., Kolomietz E., et al. Fatal lung fibrosis associated with immunodeficiency and gonadal dysgenesis in 46XX sisters - a new syndrome. Am. J. Med. Genet. A 2008, 146A:8-14.
50. Toubi E., Shoenfeld Y. Protective autoimmunity in cancer (review). Oncol. Rep. 2007, 17:245-251.
51. Scriabine A., Rabin D.U. New developments in the therapy of pulmonary fibrosis. Adv. Pharmacol. 2009, 57:419-464.
52. Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
53. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
54. King T.E., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., et al. Aphase 3 trial of Pirfenidone in patients with idiopathic pulmonary fibrosis. N.Engl. J. Med. 2014, 370:2083-2092.